Mawari, which focuses on real-time delivery of AI-powered immersive 3D experiences, has launched its public Guardian Node Offering under the Decentralised Infrastructure Offering (DIO) model. The ...

In a murine diet-induced obesity (DIO) model, after 25 days of treatment, results demonstrated: Greater than 30% weight loss when nimacimab was combined with the dual GLP-1/GIP agonist, tirzepatide ...

Mawari, a pioneer in real‑time delivery of AI‑driven immersive 3D experiences, today unveiled its public Guardian Node Offering under the Decentralized Infrastructure Offering (DIO) model. The ...

With the DIO model, everyday users become active infrastructure providers, enabling low-latency delivery of AI-generated and XR content across a decentralized network ...

The public DIO, launching on July 30th on nodes.mawari.net, will offer the remaining 160,508 Guardian Nodes to Non-U.S. participants only, pursuant to Regulation S under the U.S. Securities Act of ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates ...